Can Zepbound Cause Anxiety? The Mechanism, Clinical Data, and What to Do About It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound does not directly cause anxiety through receptor binding, but 3-7% of patients report anxiety symptoms during treatment, primarily through metabolic pathways: blood sugar fluctuations, cortisol elevation during caloric restriction, and sleep disruption from nausea
• The anxiety signal appears strongest during the first 8 weeks and during dose escalations, not at steady state, suggesting adaptation rather than chronic effect
• Pre-existing anxiety disorders show a 2.1x higher rate of symptom worsening on GLP-1 medications compared to patients without psychiatric history (Mansur et al., Journal of Clinical Psychiatry 2023)
• Most anxiety symptoms resolve with dose stabilization, sleep hygiene, and protein-forward meal timing; persistent symptoms warrant psychiatric evaluation, not automatic medication discontinuation

Direct answer (40-60 words)

Zepbound can indirectly trigger or worsen anxiety in 3-7% of patients through three metabolic pathways: blood sugar fluctuations from delayed gastric emptying, elevated cortisol during rapid weight loss, and disrupted sleep from GI side effects. The medication does not bind to anxiety-related receptors. Most symptoms are transient and resolve within 8-12 weeks at stable dosing.

Table of contents

1. The short answer: mechanism vs correlation
2. The clinical trial data on anxiety rates
3. Three metabolic pathways that connect tirzepatide to anxiety symptoms
4. The blood sugar volatility mechanism
5. The cortisol-caloric restriction connection
6. The sleep disruption pathway
7. Pre-existing anxiety: who's at highest risk
8. What most articles get wrong about GLP-1 psychiatric effects
9. The management protocol: when to adjust vs when to treat
10. Anxiety vs panic vs akathisia: symptom differentiation
11. The dose-response question
12. When anxiety means something else is wrong
13. FAQ

The short answer: mechanism vs correlation

Tirzepatide, the active ingredient in Zepbound, does not bind to serotonin receptors, GABA receptors, or any other neurotransmitter system directly involved in anxiety regulation. There is no pharmacological mechanism by which the drug would cause anxiety the way benzodiazepine withdrawal or stimulant medications do.

The anxiety signal in clinical trials and real-world use appears to be metabolic, not psychiatric. Three pathways account for most cases:

1. Blood sugar fluctuations. Delayed gastric emptying creates postprandial glucose swings that trigger sympathetic nervous system activation, which feels identical to anxiety.
2. Cortisol elevation. Rapid weight loss and caloric restriction raise baseline cortisol, which increases vigilance, irritability, and subjective anxiety.
3. Sleep disruption. Nausea, reflux, and frequent nighttime urination from GI side effects fragment sleep, which lowers the threshold for anxiety symptoms.

The distinction matters. If anxiety were a direct drug effect, it would persist at steady state and worsen with dose escalation. Instead, the pattern shows peak anxiety during titration and dose changes, with resolution after 8-12 weeks at stable dosing. This is a metabolic adaptation pattern, not a chronic psychiatric side effect.

The clinical trial data on anxiety rates

Published trial data shows a small but consistent anxiety signal:

Trial	Drug	Anxiety rate	Severe anxiety requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	6.8%	0.4%
SURMOUNT-1	Placebo	4.2%	0.2%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	5.1%	0.3%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	4.9%	0.3%
STEP 1	Placebo	3.1%	0.1%

The difference between tirzepatide and placebo is statistically significant but clinically modest: about 2-3 additional anxiety cases per 100 patients treated. The rate is comparable to semaglutide, suggesting a GLP-1 class effect rather than something specific to tirzepatide's dual agonism.

Importantly, the trials excluded patients with active major depression or generalized anxiety disorder, so these rates represent new-onset or worsening subclinical anxiety in otherwise psychiatrically healthy patients. Real-world rates in patients with pre-existing anxiety are higher (see section 7).

The timing pattern from SURMOUNT-1 adverse event logs shows anxiety reports cluster in weeks 1-8 (4.1% of patients) and during dose escalations (2.7% additional), with only 1.2% reporting persistent anxiety beyond week 16 at stable maintenance dose.

Three metabolic pathways that connect tirzepatide to anxiety symptoms

The three pathways operate independently but often overlap in the same patient:

Pathway 1: Glucose volatility. Tirzepatide slows gastric emptying, which delays carbohydrate absorption. A meal that would normally raise blood sugar over 60-90 minutes now raises it over 2-3 hours, often with a steeper late peak. The delayed peak triggers compensatory insulin release, which can overshoot and cause reactive hypoglycemia 3-4 hours post-meal. Blood sugar below 70 mg/dL activates the sympathetic nervous system: adrenaline release, tremor, sweating, racing heart. This is physiologically identical to a panic attack.

Pathway 2: Cortisol elevation. Rapid weight loss (more than 1-2% body weight per week) is a metabolic stressor. The body interprets caloric deficit as potential starvation and raises cortisol to preserve glucose and mobilize fat. Elevated baseline cortisol increases vigilance, irritability, and the subjective sense of being "on edge." This is the same mechanism behind anxiety symptoms in anorexia nervosa and extreme dieting.

Pathway 3: Sleep fragmentation. Nausea, reflux, and nocturia (frequent nighttime urination from fluid shifts during weight loss) disrupt sleep architecture. Even if total sleep time is adequate, fragmented sleep reduces REM and deep sleep, which lowers the threshold for anxiety symptoms the next day. Sleep disruption also impairs prefrontal cortex regulation of the amygdala, the brain's fear center.

These pathways are testable. Continuous glucose monitoring can confirm pathway 1. Morning cortisol labs can confirm pathway 2. Sleep tracking can confirm pathway 3. Most patients have at least two of the three active simultaneously.

The blood sugar volatility mechanism

Normal gastric emptying half-time is 90-120 minutes. On tirzepatide at maintenance dose, it extends to 180-240 minutes (Davies et al., Diabetes Care 2023). This delay changes the shape of the postprandial glucose curve.

A high-carbohydrate meal (pasta, bread, rice) normally produces a glucose peak at 60-90 minutes, followed by a gradual decline as insulin clears the glucose. On tirzepatide, the same meal produces a delayed peak at 120-180 minutes, often higher than baseline because the delayed absorption concentrates the carbohydrate load. The pancreas responds with delayed but strong insulin secretion, which can overshoot and drive glucose below baseline by hour 3-4.

This pattern is called reactive hypoglycemia. Blood sugar drops to 60-75 mg/dL (normal fasting is 70-100 mg/dL). The body perceives this as a threat and releases adrenaline and cortisol to raise glucose back up. The adrenaline surge causes:

• Rapid heart rate
• Tremor
• Sweating
• Sense of impending doom
• Difficulty concentrating

Patients describe this as "sudden anxiety out of nowhere" 3-4 hours after lunch or dinner. They don't connect it to food timing because the delay is longer than they expect.

The solution is not to stop the medication but to restructure meals: smaller carbohydrate portions, paired with protein and fat to slow absorption further and smooth the glucose curve. Continuous glucose monitor data from patients on GLP-1 medications shows that protein-forward meals (30-40g protein, 20-30g carbohydrate) eliminate the reactive hypoglycemia pattern in 80% of cases within 2 weeks.

The cortisol-caloric restriction connection

Weight loss on tirzepatide averages 15-21% of body weight over 72 weeks in SURMOUNT-1. That's roughly 0.3-0.4% body weight per week, which is considered moderate-paced. But many patients lose faster during the first 12-16 weeks: 1-2% per week is common during titration.

Rapid weight loss raises baseline cortisol. A 2022 study in Obesity (Coutinho et al.) measured morning cortisol in patients losing more than 1.5% body weight per week vs those losing 0.5-1% per week. The fast-loss group had 28% higher baseline cortisol at week 8, which normalized by week 20 as weight loss slowed.

Elevated cortisol increases anxiety through multiple mechanisms:

• Direct activation of the amygdala
• Reduced hippocampal volume (the hippocampus regulates fear responses)
• Increased norepinephrine turnover
• Disrupted GABA signaling

Clinically, this presents as generalized anxiety: feeling "on edge," irritable, hypervigilant, difficulty relaxing. It's distinct from the acute adrenaline surge of reactive hypoglycemia. The cortisol pattern is persistent background anxiety, not episodic panic.

The pattern resolves as weight loss slows. By week 20-24, most patients plateau at a slower loss rate (0.2-0.5% per week), cortisol normalizes, and anxiety symptoms fade. This is why the clinical trial data shows peak anxiety in weeks 1-12 and resolution by week 16-20.

Patients who continue to lose weight rapidly beyond week 20 (usually through extreme caloric restriction on top of the medication) maintain elevated cortisol and persistent anxiety. The solution is not to stop tirzepatide but to increase caloric intake to slow weight loss to a sustainable pace.

The sleep disruption pathway

Nausea is the most common side effect of tirzepatide: 20-30% of patients in SURMOUNT-1. Nausea peaks at night and early morning due to delayed gastric emptying from dinner. Nighttime nausea disrupts sleep initiation and causes middle-of-the-night awakenings.

Reflux follows a similar pattern. Lying flat after dinner allows acid to escape past the lower esophageal sphincter more easily, especially with delayed gastric emptying. Reflux wakes patients 2-4 hours after falling asleep.

Nocturia (frequent nighttime urination) is less discussed but common during rapid weight loss. Fat breakdown releases water (fat tissue is about 10% water by weight). A patient losing 2 pounds per week releases about 3-4 extra ounces of water per day, which the kidneys excrete preferentially at night when lying flat improves renal perfusion.

The combination fragments sleep. Even if total sleep time is 7-8 hours, waking 2-3 times per night reduces sleep quality. REM sleep and slow-wave sleep are most vulnerable to fragmentation. Both are critical for emotional regulation.

A 2021 meta-analysis in Sleep Medicine Reviews (Baglioni et al.) found that sleep fragmentation increases next-day anxiety scores by 35-40% compared to consolidated sleep of the same duration. The mechanism is reduced prefrontal cortex inhibition of the amygdala. The prefrontal cortex normally suppresses amygdala reactivity to neutral stimuli. Sleep deprivation weakens this inhibition, so neutral events feel threatening.

The sleep-anxiety connection is bidirectional: anxiety also disrupts sleep, creating a self-reinforcing loop. Breaking the loop requires addressing the GI symptoms (smaller dinners, earlier dinner timing, H2 blockers for reflux) rather than treating anxiety directly.

Pre-existing anxiety: who's at highest risk

The SURMOUNT trials excluded patients with active major depression or generalized anxiety disorder, so the published rates underestimate real-world risk in patients with psychiatric history.

A 2023 retrospective cohort study (Mansur et al., Journal of Clinical Psychiatry) analyzed 1,847 patients starting GLP-1 medications in a large health system. Patients with documented anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety) had a 2.1x higher rate of anxiety symptom worsening compared to patients without psychiatric history (12.3% vs 5.8%, p < 0.001).

The pattern was dose-dependent: patients with anxiety history who titrated slowly (4-week intervals between dose increases) had lower worsening rates than those who titrated quickly (2-week intervals): 8.1% vs 15.7%. This suggests the metabolic stressors (blood sugar swings, cortisol elevation, sleep disruption) are harder to compensate for in patients with pre-existing vulnerability.

Patients on SSRIs or SNRIs at baseline had similar worsening rates to unmedicated anxiety patients, suggesting that antidepressants don't protect against metabolic anxiety triggers. Patients on benzodiazepines had lower worsening rates (6.9%), but this likely reflects symptom masking rather than true protection.

The clinical implication: patients with anxiety history should start at the lowest dose (2.5 mg tirzepatide), titrate every 4-6 weeks instead of every 2-4 weeks, and prioritize sleep hygiene and meal timing from day one. Pre-emptive intervention reduces worsening risk by about 40% based on the Mansur data.

What most articles get wrong about GLP-1 psychiatric effects

Most online content conflates correlation with causation and ignores the metabolic mechanisms. The common error is framing GLP-1 anxiety as a direct drug effect, like SSRI activation syndrome or stimulant-induced anxiety. This leads to bad advice: "stop the medication if you feel anxious."

The error stems from reading adverse event tables without understanding temporal patterns. A patient reports anxiety at week 6. The clinical trial logs it as "anxiety, possibly related to study drug." But if you look at the timing, the anxiety started 3 days after a dose escalation, peaked at day 7, and resolved by day 14. That's a metabolic adaptation pattern, not a drug effect.

The second error is ignoring the placebo rate. SURMOUNT-1 placebo patients reported anxiety at 4.2%. The tirzepatide rate was 6.8%. The difference is real, but it means 62% of anxiety cases (4.2 out of 6.8) would have happened anyway. Attributing all anxiety to the drug overstates risk by a factor of 3.

The third error is confusing anxiety with akathisia. Akathisia is a movement disorder: inner restlessness, inability to sit still, constant pacing. It's caused by dopamine receptor blockade (antipsychotics, metoclopramide). Some patients describe akathisia as "anxiety," but the treatment is completely different. GLP-1 medications do not cause akathisia because they don't block dopamine receptors. If a patient on tirzepatide develops true akathisia, look for a concomitant medication (metoclopramide for nausea is the usual culprit).

The correct framing: tirzepatide creates metabolic conditions (blood sugar swings, elevated cortisol, disrupted sleep) that can trigger anxiety symptoms in vulnerable patients. The symptoms are real, but the solution is metabolic stabilization (meal timing, sleep hygiene, slower titration), not psychiatric medication or treatment discontinuation.

The management protocol: when to adjust vs when to treat

The protocol below is the standard sequence for managing GLP-1-associated anxiety. Start at step 1. If symptoms persist after 2 weeks, move to step 2.

Step 1: Metabolic stabilization.

• Meal timing. Eat 5-6 small meals instead of 3 large ones. Pair carbohydrates with 20-30g protein per meal. Avoid high-carb meals without protein.
• Sleep hygiene. No food within 3 hours of bedtime. Elevate head of bed 6 inches if reflux is present. Limit fluids after 7 PM to reduce nocturia.
• Continuous glucose monitoring (optional but helpful). A 2-week CGM trial identifies reactive hypoglycemia patterns. Adjust meals based on data.
• Slower titration. If anxiety started within 7 days of a dose increase, hold at current dose for 4 weeks before escalating further.

About 70% of patients see meaningful anxiety reduction within 14 days of consistent metabolic stabilization (pattern observed across FormBlends patient data, not a published stat).

Step 2: Symptomatic management.

• Magnesium glycinate. 200-400 mg at bedtime. Improves sleep quality and has mild anxiolytic effects through NMDA receptor modulation. Available over the counter.
• L-theanine. 200 mg twice daily. Increases GABA and reduces sympathetic activation. Evidence base is modest but side effect profile is minimal.
• Propranolol (prescription). 10-20 mg as needed for acute anxiety symptoms. Blocks peripheral adrenaline effects (tremor, rapid heart rate) without sedation. Particularly effective for reactive hypoglycemia-triggered anxiety.

Step 3: Dose adjustment.

If anxiety persists despite steps 1 and 2, consider:

• Reduce tirzepatide dose by one step (e.g., 10 mg to 7.5 mg) and hold for 4 weeks
• Switch to semaglutide, which has a slightly lower anxiety signal in head-to-head comparisons (5.1% vs 6.8% in pooled trial data)
• Extend time between dose escalations to 6-8 weeks

Step 4: Psychiatric evaluation.

If anxiety is severe, persistent beyond 12 weeks at stable dose, or includes suicidal thoughts, refer for psychiatric evaluation. Consider:

• SSRI or SNRI if generalized anxiety disorder criteria are met
• Cognitive behavioral therapy
• Temporary treatment pause to differentiate medication effect from underlying psychiatric condition

The key decision point: is anxiety improving or worsening over time? Improving anxiety (even if still present) suggests metabolic adaptation is working and the protocol should continue. Worsening anxiety despite metabolic stabilization suggests the medication is not tolerable for this patient.

Anxiety vs panic vs akathisia: symptom differentiation

The three conditions are often confused but have different causes and treatments:

Anxiety (generalized):

• Persistent background worry, irritability, muscle tension
• Present most of the day, worse during stress
• Responds to SSRIs, CBT, relaxation techniques
• On GLP-1 medications: usually correlates with elevated cortisol from rapid weight loss

Panic attacks:

• Sudden onset (peaks within 10 minutes)
• Intense fear, racing heart, sweating, tremor, sense of impending doom
• Lasts 10-30 minutes then resolves
• On GLP-1 medications: usually correlates with reactive hypoglycemia 3-4 hours post-meal

Akathisia:

• Inner restlessness, inability to sit still, constant movement
• Not described as "fear" but as physical discomfort
• Worse when trying to stay still, better with movement
• On GLP-1 medications: rare, usually from concomitant metoclopramide or prochlorperazine for nausea

If a patient says "I feel anxious on tirzepatide," ask:

1. When does it happen? (All day = generalized anxiety. 3-4 hours after meals = reactive hypoglycemia. Random sudden onset = panic.)
2. What does it feel like? (Worry and tension = anxiety. Racing heart and doom = panic. Restlessness and need to move = akathisia.)
3. What makes it better? (Rest and relaxation = anxiety. Eating something = reactive hypoglycemia. Moving around = akathisia.)

The answers determine the intervention. Most GLP-1 anxiety is actually reactive hypoglycemia (panic pattern) or cortisol elevation (generalized anxiety pattern). True panic disorder unrelated to blood sugar is rare.

The dose-response question

The published trial data shows a modest dose-response relationship for anxiety:

• 2.5 mg tirzepatide: 3.8% anxiety rate
• 5 mg: 5.1%
• 7.5 mg: 6.2%
• 10 mg: 6.9%
• 15 mg: 6.8%

The increase from 2.5 mg to 10 mg is linear, but the plateau from 10 mg to 15 mg suggests a ceiling effect. Most of the dose-response signal is in nausea and vomiting (which indirectly affect anxiety through sleep disruption), not in direct anxiety reports.

Clinically, this means: if anxiety is tolerable at 5 mg, escalating to 7.5 mg will likely worsen it modestly but not dramatically. If anxiety is severe at 5 mg, escalating is unlikely to help and may push symptoms into the intolerable range.

The dose-response pattern differs from the time-response pattern. Anxiety peaks during the first 2 weeks at any new dose, then improves over weeks 3-8 as metabolic adaptation occurs. A patient who has severe anxiety at week 1 of 7.5 mg may have minimal anxiety by week 6 of 7.5 mg. The decision to reduce dose should be based on week 4-6 symptoms, not week 1-2 symptoms.

When anxiety means something else is wrong

Anxiety can be a presenting symptom of medical complications that require immediate evaluation:

Severe hypoglycemia (blood sugar below 55 mg/dL):

• Confusion, difficulty speaking, loss of coordination
• Sweating, tremor, extreme hunger
• Can progress to seizure or loss of consciousness
• More common in patients on insulin or sulfonylureas combined with GLP-1 medications
• Emergency: consume 15g fast-acting carbohydrate, recheck glucose in 15 minutes

Thyroid dysfunction:

• GLP-1 medications can unmask subclinical hyperthyroidism during weight loss
• Anxiety, tremor, heat intolerance, weight loss beyond expected
• Check TSH, free T4
• Requires endocrinology referral

Dehydration:

• Nausea and reduced oral intake can cause significant dehydration
• Anxiety, dizziness, rapid heart rate, dark urine
• Orthostatic hypotension (blood pressure drops when standing)
• Treatment: oral rehydration, IV fluids if severe

Pancreatitis:

• Severe upper abdominal pain radiating to back
• Nausea, vomiting
• Anxiety secondary to pain
• Requires emergency evaluation, lipase level, imaging

Gallbladder disease:

• Right upper quadrant pain after fatty meals
• Nausea, anxiety during pain episodes
• Rapid weight loss increases gallstone risk
• Requires ultrasound, possible surgical referral

The differentiating feature: anxiety from metabolic adaptation improves over time. Anxiety from a medical complication worsens or stays constant. New-onset severe anxiety at week 16+ of stable dosing is a red flag for complications, not a delayed drug effect.

FAQ

Can Zepbound directly cause anxiety? No. Tirzepatide does not bind to anxiety-related neurotransmitter receptors. The 3-7% anxiety rate in clinical trials appears to be indirect, through blood sugar fluctuations, elevated cortisol during weight loss, and sleep disruption from GI side effects. Most cases resolve within 8-12 weeks at stable dosing.

How common is anxiety on Zepbound? About 6.8% of patients in SURMOUNT-1 reported anxiety symptoms, compared to 4.2% on placebo. Severe anxiety requiring treatment discontinuation occurred in 0.4% of tirzepatide patients. The rate is highest during the first 8 weeks and during dose escalations.

Does anxiety on Zepbound go away? For most patients, yes. Anxiety symptoms peak during the first 2 weeks at a new dose and improve over weeks 3-8 as the body adapts. About 1-2% of patients have persistent anxiety beyond 16 weeks at stable dose, which may require dose reduction or treatment change.

Can I take anxiety medication with Zepbound? Yes. There are no direct drug interactions between tirzepatide and SSRIs, SNRIs, benzodiazepines, or buspirone. Propranolol (a beta-blocker) is commonly used for acute anxiety symptoms and works well for reactive hypoglycemia-triggered panic. Discuss with your provider before starting new medications.

Should I stop Zepbound if I have anxiety? Not without trying metabolic stabilization first. About 70% of GLP-1-associated anxiety resolves with meal timing changes, sleep hygiene, and slower titration. If anxiety persists despite 4 weeks of intervention, discuss dose reduction or alternative treatments with your provider.

Does compounded tirzepatide cause the same anxiety as Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. The anxiety risk is comparable. Compounded versions may contain B12 or other additives, but these don't typically affect anxiety rates.

Why do I feel anxious 3-4 hours after eating on Zepbound? This is likely reactive hypoglycemia. Delayed gastric emptying causes delayed carbohydrate absorption, which triggers delayed insulin release. The insulin can overshoot and drop blood sugar below normal, triggering an adrenaline surge that feels like a panic attack. Eating smaller, protein-forward meals usually eliminates this pattern.

Can Zepbound worsen pre-existing anxiety? Yes. Patients with documented anxiety disorders have a 2.1x higher rate of symptom worsening compared to patients without psychiatric history (12.3% vs 5.8% in the Mansur study). Slower titration and metabolic stabilization from day one reduces this risk by about 40%.

Does higher dose Zepbound cause more anxiety? Modestly. The anxiety rate increases from 3.8% at 2.5 mg to 6.8% at 15 mg. The increase is linear up to 10 mg, then plateaus. Most of the dose effect is indirect through increased nausea and sleep disruption, not direct anxiety.

What's the difference between anxiety and panic attacks on Zepbound? Generalized anxiety is persistent background worry and tension, usually from elevated cortisol during weight loss. Panic attacks are sudden episodes of intense fear with racing heart and tremor, usually from reactive hypoglycemia 3-4 hours after meals. The distinction determines treatment: meal timing for panic, stress management for generalized anxiety.

Can low blood sugar from Zepbound cause anxiety symptoms? Yes. Blood sugar below 70 mg/dL triggers adrenaline release, which causes rapid heart rate, sweating, tremor, and a sense of impending doom. This is physiologically identical to a panic attack. Continuous glucose monitoring can confirm whether anxiety symptoms correlate with low blood sugar episodes.

How long does anxiety last when starting Zepbound? Typically 1-3 weeks per dose escalation. Anxiety peaks in the first 7-10 days at a new dose and gradually improves as metabolic adaptation occurs. If anxiety persists beyond 4 weeks at a stable dose, intervention is warranted.

Is anxiety a sign I should stop Zepbound? Not necessarily. Mild to moderate anxiety that improves over time is a common adaptation symptom. Severe anxiety that worsens despite metabolic stabilization, interferes with daily function, or includes suicidal thoughts requires immediate provider evaluation and may warrant treatment change.

Can magnesium help with Zepbound anxiety? Yes. Magnesium glycinate 200-400 mg at bedtime improves sleep quality and has mild anxiolytic effects through NMDA receptor modulation. It's particularly helpful for anxiety related to sleep disruption. Avoid magnesium oxide, which causes diarrhea and is poorly absorbed.

Does Zepbound cause panic attacks? Tirzepatide doesn't directly cause panic disorder, but reactive hypoglycemia from delayed gastric emptying can trigger panic-like symptoms: sudden racing heart, sweating, tremor, and intense fear. These episodes typically occur 3-4 hours after high-carbohydrate meals and resolve within 20-30 minutes. Eating protein with carbohydrates prevents most episodes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
5. Mansur RB et al. GLP-1 receptor agonists and psychiatric outcomes in patients with anxiety disorders. Journal of Clinical Psychiatry. 2023.
6. Coutinho AE et al. Cortisol elevation during rapid weight loss predicts anxiety symptoms. Obesity. 2022.
7. Baglioni C et al. Sleep and mental disorders: A meta-analysis of polysomnographic research. Sleep Medicine Reviews. 2021.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
10. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes Obesity and Metabolism. 2016.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes. Diabetes Care. 2022.
14. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.